Cargando…

Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials

BACKGROUND: To summarise specific adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir in patients with COVID-19. METHODS: We searched 32 databases through 27 October 2020. We included randomised trials comparing any of the drugs of interest to placebo or standard care, or again...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izcovich, Ariel, Siemieniuk, Reed Alexander, Bartoszko, Jessica Julia, Ge, Long, Zeraatkar, Dena, Kum, Elena, Qasim, Anila, Khamis, Assem M, Rochwerg, Bram, Agoritsas, Thomas, Chu, Derek K, McLeod, Shelley L, Mustafa, Reem A, Vandvik, Per, Brignardello-Petersen, Romina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Infectious Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895418/ https://www.ncbi.nlm.nih.gov/pubmed/35236729 http://dx.doi.org/10.1136/bmjopen-2020-048502

Ejemplares similares

Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis
por: Zeraatkar, Dena, et al.
Publicado: (2022)

A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19
por: Maciorowski, Dawid, et al.
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
por: Uzunova, Katya, et al.
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality
por: Honarmand, Kimia, et al.
Publicado: (2021)

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
por: Siemieniuk, Reed AC, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Bradycardia and off-label-use: case report
Publicado: (2021)

Minimal important differences for improvement in shoulder condition patient-reported outcomes: a systematic review to inform a BMJ Rapid Recommendation
por: Hao, Qiukui, et al.
Publicado: (2019)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
por: Qomara, Windi Fresha, et al.
Publicado: (2021)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19
por: Echarte-Morales, Julio, et al.
Publicado: (2021)

Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
por: Schneider, Johanna, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Guillain-Barre-syndrome and off-label-use: case report
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy and off label use: 3 case reports
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy following off-label use: case report
Publicado: (2022)

Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir
por: Yin, Guosheng, et al.
Publicado: (2020)

Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: a protocol of a META-epidemiological study
por: Jimenez-Mora, Mario A., et al.
Publicado: (2021)

Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review
por: Zeraatkar, Dena, et al.
Publicado: (2022)

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
por: Ader, Florence
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir/tocilizumab: Lack of efficacy following off label use: case report
Publicado: (2022)

Lopinavir/ritonavir/remdesivir: Drug induced liver injury and off label use: 5 case reports
Publicado: (2020)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
por: Sheahan, Timothy P., et al.
Publicado: (2020)

Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial
por: Nekoukar, Zahra, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Acute generalised exanthematous pustulosis with erythema multiforme-like lesions: case report
Publicado: (2020)

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
por: Arabi, Yaseen M., et al.
Publicado: (2021)

747. Antibiotic Therapy for Community-Acquired Pneumonia: A Systematic Review and Network Meta-Analysis of Randomized Trials
por: Siemieniuk, Reed, et al.
Publicado: (2018)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Hydroxychloroquine/lopinavir/ritonavir/methylprednisolone: Manic episode with psychotic features during an off-label use: case report
Publicado: (2020)

Azithromycin/hydroxychloroquine/lopinavir/ritonavir: Brugada-like ECG pattern following off-label use: case report
Publicado: (2021)

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
por: Kim, Ji-Won, et al.
Publicado: (2021)

Hydroxychloroquine/lopinavir/ritonavir: Drug ineffectiveness following off-label use in COVID-19 infection: case report
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Vomiting and QTc-interval prolongation following off-label therapy: 2 case reports
Publicado: (2021)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort
por: Karolyi, Mario, et al.
Publicado: (2020)

Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre
por: Istampoulouoglou, Ioanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hte0ml06q525eu47fbbskdn8g2